NasdaqCM - Delayed Quote USD

Intensity Therapeutics, Inc. (INTS)

0.4752
+0.0862
+(22.16%)
At close: May 30 at 4:00:00 PM EDT
0.4352
-0.04
(-8.42%)
After hours: May 30 at 7:41:15 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INTS

Recent News: INTS

View More
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
PR Newswire 2 days ago
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
PR Newswire 3 days ago
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire 17 days ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
PR Newswire 25 days ago
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
PR Newswire last month
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Zacks last month
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Zacks last month
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
PR Newswire 2 months ago
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR Newswire 3 months ago
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
PR Newswire 4 months ago
Intensity Therapeutics reports positive results of INT230-6 in breast cancer

Intensity Therapeutics reports positive results of INT230-6 in breast cancer
TipRanks 5 months ago
View More

Related Tickers

ENTO Entero Therapeutics, Inc.
0.4335
+5.22%
 
PCSA Processa Pharmaceuticals, Inc.
0.2925
-3.53%
 
INDP Indaptus Therapeutics, Inc.
0.3380
-15.50%
 
AEON AEON Biopharma, Inc.
0.5760
-4.38%
 
PASG Passage Bio, Inc.
0.4363
-3.41%
 
ATHA Athira Pharma, Inc.
0.3125
+10.54%
 
KLTO Klotho Neurosciences, Inc.
0.1820
-4.96%
 
ABP Abpro Holdings, Inc.
0.2137
-8.28%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6274
-4.78%
 
GBIO Generation Bio Co.
0.3782
-2.58%